ABT vs BSX
ABT and BSX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | ABTABBOTT LABORATORIES | BSXBOSTON SCIENTIFIC CORPORATION |
|---|---|---|
| Market cap | $185.05B | $60.82B |
| P/E (TTM) | 29.8 | 17.0 |
| P/B | 3.55 | 2.44 |
| P/S | 4.2x | 3.0x |
| Dividend yield | 2.22% | — |
| Revenue | $45.13B(TTM) | $21.00B(TTM) |
| Revenue growth (YoY) | 5.7% | 19.9% |
| Net income | $6.28B(TTM) | $3.67B(TTM) |
| Earnings growth (YoY) | -51.3% | 56.7% |
| EPS, diluted | $3.57(TTM) | $2.47(TTM) |
| EBIT margin | 18.2% | 18.0% |
| ROE | 12.5% | 11.6% |
| ROIC | 8.3% | 10.0% |
| Piotroski F | — | 8/9 |
| 1y total return | -12.9% | -58.3% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: ABT vs BSX
| Metric | ABT | BSX |
|---|---|---|
| End value | $33.7K | $18.2K |
| Total return | +236.5% | +82.3% |
| CAGR | +12.5% | +6.0% |
| Volatility | 23.9% | 27.5% |
| Sharpe | 0.44 | 0.20 |
| Sortino | 0.63 | 0.27 |
| Max drawdown | -39.6% | -61.5% |
Based on 2600 common trading days, 2016-06-29 → 2026-10-30 · risk-free 4.16% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)